FOLH1 and prostate carcinoma: The prostate-specific membrane antigen (PSMA)–targeted radiohybrid (rh) ligand [177Lu]Lu-rhPSMA-7.3 has recently been assessed in a pretherapeutic dosimetry study on prostate cancer patients.